Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

CASE DETAILS: According to the complaint, on December 20, 2024, Novo issued a press release announcing the below-expected results of their "REDEFINE 1" trial, "a 68-week efficacy and safety trial ...

we used a temporary price dislocation caused by disappointing clinical trial results to purchase shares of Novo Nordisk A/S (NYSE:NVO), a Danish-based leader in diabetes and obesity treatments.

The glucagon-like peptide-1 (GLP-1) analogue is already a big earner for Novo Nordisk in a lower 1.8g formulation - Victoza - that is used to treat type 2 diabetes and achieved sales of 9.4 ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with ... "From my point of view as a doctor, you don't get [diabetes, obesity, chronic kidney disease and ...

US FDA Approves Novo Nordisk's Ozempic to Cut Risk of Diabetic ... agonists and has the same active ingredient as its popular obesity treatment Wegovy. The U.S. Food and Drug Administration's ...

Novo Nordisk (NYSE:NVO) A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE ...

Novo Nordisk's phase 3 CagriSema study on obesity, named "REDEFINE-1." Defendants' statements failed to disclose or otherwise misled investors as to the nature of the dosages provided to patients ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...